Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CHD1L |
| Gene Name: | CHD1L |
| Protein Full Name: | Chromodomain-helicase-DNA-binding protein 1-like |
| Alias: | Amplified in liver cancer protein 1 |
| Mass (Da): | 100982 |
| Number AA: | 897 |
| UniProt ID: | Q86WJ1 |
| Locus ID: | 9557 |
| COSMIC ID: | CHD1L |
| Gene location on chromosome: | 1q21.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19838 |
| Percent of cancer specimens with mutations: | 0.67 |
| Found in amplified chromosomal regions in human cancers: | Hepatocellular carcinoma(58%-78%); OMIM |
| Normal role description: | CHD1L is a DNA helicase involved in the DNA damage repair mechanism. CHD1L has chromatin remodeling capabilities and can catalyze nucleosome sliding along DNA through hydrolysis of ATP leading to cause a more relaxed state of DNA. CHD1L recognizes damaged DNA through binding of poly(ADP-ribose), a marker of DNA damage deposited by Poly (ADP-ribose) polymerase (PARP). CHD1L has been implicated in the development of hepatocellular carcinoma (HCC). Overexpression of CHD1L has been observed in HCC cases and was found to result in increased DNA synthesis by promoting the G1/S phase transition. CDH1L has also been found to cause downregulation of tumour suppresor proteins; p53 and p21, and pro-apoptotic factors; PPC3, BAX, while upregulating cell cycle progressors; CDK2 and cyclin E. Furthermore, knockdown of CHD1L by RNAi reduced CHD1L mediated DNA synthesis in HCC cell lines. |